Drugs / EDP239
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02173574 | Aug → Nov 2014 | hepatitis C virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01856426 | Jun 2013 → Nov 2014 | chronic hepatitis C virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-10-01 | Enanta Pharmaceuticals, Inc | Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis enanta.com ↗ |
| 2014-08-07 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals’ HCV NS5A Inhibitor EDP-239 Advances into Combination Studies with Alisporivir (DEB025) enanta.com ↗ |
| 2011-09-26 | Enanta Pharmaceuticals, Inc | Enanta’s Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover’s Top 10 Infectious Disease Projects to Watch enanta.com ↗ |
| 2010-03-02 | Enanta Pharmaceuticals, Inc | Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program enanta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP239 | “Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.” PMID 27503640 ↗ Sep 2016 |
| Action | Inhibit | “EDP-239 is a potent, selective inhibitor with potency at picomolar to nanomolar concentrations against HCV genotypes 1 through 6.” PMID 27503640 ↗ Sep 2016 |